ImmunoPrecise Antibodies
A Canada-based supplier of custom hybridoma development services.
- Healthcare
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $12.0m Valuation: $12.0m 0.7x EV/Revenue -2.3x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| CAD | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 8 % | 7 % | 19 % | - | 18 % | 32 % | 14 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (63 %) | (103 %) | (33 %) | (29 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (86 %) | (129 %) | (111 %) | (123 %) | (24 %) | 7 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 35 % | 59 % | 16 % | 20 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
ImmunoPrecise Antibodies (IPA) began its journey in the biotech industry with a mission to revolutionize the way therapeutic antibodies are discovered and developed. Founded by Dr. James Kuo, the company set out to address the inefficiencies in traditional antibody development processes.
Under Dr. Kuo's leadership, IPA focused on integrating cutting-edge technologies to streamline antibody discovery. This approach not only accelerated the development timeline but also enhanced the precision and efficacy of the antibodies produced. The company's innovative platform quickly gained attention, positioning IPA as a leader in the field of therapeutic antibody development.
A significant milestone in IPA's journey was its successful listing on the NASDAQ, which provided the company with the capital needed to expand its research capabilities and explore new therapeutic areas. This move was pivotal in attracting strategic partnerships and collaborations with major pharmaceutical companies, further solidifying IPA's reputation in the biotech industry.
Throughout its history, ImmunoPrecise Antibodies has remained committed to its core mission of improving patient outcomes through innovative antibody therapies. The company's journey is a testament to the impact of visionary leadership and technological innovation in transforming the landscape of biotech research and development.
Tech stack
Investments by ImmunoPrecise Antibodies
Edit
